Tianjin Yugen Medtech Development Co., Ltd. announced a private placement of CNY 100 million on July 2, 2021. The transaction included participation from new investor Tianjin Tianhao Management Consulting Partnership Enterprise (Limited Partnership) will subscribe to registered capital of CNY 3,418,800 for CNY 20 million, returning investors Asymchem Laboratories (Tianjin) Co., Ltd. will subscribe to registered capital of CNY 4,444,400 for CNY 26 million, Tianjin Haihe Kailaiying Biopharmaceutical Industry Innovation Investment Fund (L.P.), a fund managed by Haiying Chuang (Tianjin) Investment Management Co., Ltd. will subscribe to registered capital of CNY 4,102,600 for CNY 24 million, Heji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will subscribe to registered capital of CNY 1,367,500 for CNY 8 million and Jinji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will subscribe to registered capital of CNY3,760,700 for CNY22 million. On post completion, Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) will acquire 29.08% stake, Tianjin Haihe Kailaiying Biopharmaceutical Industry Innovation Investment Fund (L.P.), a fund managed by Haiying Chuang (Tianjin) Investment Management Co., Ltd. will acquire 26.84% stake, Heji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will acquire 8.95% stake, Jinji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will acquire 24.60% stake and Tianjin Tianhao Management Consulting Partnership Enterprise (Limited Partnership) will acquire 10.53% stake in the company. . The transaction has been approved by the board of directors of the company at the 7th session of the company of the 4th directorate and at the 6th session of the company by the 4th supervisory board.